Please login to the form below

Not currently logged in
Email:
Password:

Baxter to acquire Prism Pharma for $338m

Baxter International has entered into an agreement to acquire Prism Pharmaceuticals, a speciality pharma company based in King of Prussia, Pennsylvania

Baxter International has entered into an agreement to acquire Prism Pharmaceuticals, a speciality pharma company based in King of Prussia, Pennsylvania in a deal worth up to $338m. 

The terms of the agreement include an upfront payment of $170m with the potential for a further $168m in future milestone payments. 

Prism's product portfolio includes the anti-arrhythmic agent Nexterone (amiodarone HCl), which is approved by the US Food and Drug Administration (FDA) for multiple presentations including the first and only ready-to-use premixed intravenous (IV) bag formulations as well as vials and a pre-filled syringe.

"Nexterone is a great addition to our leading portfolio of premix drugs and solutions for the acute care setting. It offers clinicians a unique, ready-to-use anti-arrhythmic agent for critical and time sensitive situations, while also providing convenience to caregivers and value to pharmacists," said Robert M Davis, president of Baxter's Medical Products business. "Based on our strong hospital relationships and familiarity with the product, Baxter is well-positioned to launch the ready-to-use presentations of Nexterone."

The companies expect to close the deal during the second quarter of 2011.

19th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics